Trial · NCT04773600
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 | Roflumilast Cream 0.15% | 28.9 | percentage of participants | ||
| Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 | Vehicle Cream | 12.0 | percentage of participants | ||
| Achievement of vIGA-AD Success at Week 4 in Participants With Moderate Baseline Scores | Roflumilast Cream 0.15% | 32.9 | percentage of participants | ||
| Achievement of vIGA-AD Success at Week 4 in Participants With Moderate Baseline Scores | Vehicle Cream | 13.1 | percentage of participants | ||
| vIGA-AD Success at Week 2 | Roflumilast Cream 0.15% | 17.7 | percentage of participants | ||
| vIGA-AD Success at Week 2 | Vehicle Cream | 5.3 | percentage of participants | ||
| vIGA-AD Success at Week 1 | Roflumilast Cream 0.15% | 5.9 | percentage of participants | ||
| vIGA-AD Success at Week 1 | Vehicle Cream | 3.1 | percentage of participants | ||
| Achievement of a 4-point Reduction at Week 4 in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) in Participants With Baseline WI-NRS Score ≥4 | Roflumilast Cream 0.15% | 30.2 | 95% Confidence Interval 24.77 to 36.31 | percentage of participants | |
| Achievement of a 4-point Reduction at Week 4 in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) in Participants With Baseline WI-NRS Score ≥4 | Vehicle Cream | 12.4 | 95% Confidence Interval 7.77 to 19.26 | percentage of participants | |
| Achievement of a 4-point Reduction at Week 2 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4 | Roflumilast Cream 0.15% | 22.3 | 95% Confidence Interval 17.66 to 27.82 | percentage of participants | |
| Achievement of a 4-point Reduction at Week 2 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4 | Vehicle Cream | 6.9 | 95% Confidence Interval 3.66 to 12.56 | percentage of participants | |
| Achievement of a 4-point Reduction at Week 1 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4 | Roflumilast Cream 0.15% | 11.2 | 95% Confidence Interval 7.89 to 15.57 | percentage of participants | |
| Achievement of a 4-point Reduction at Week 1 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4 | Vehicle Cream | 1.6 | 95% Confidence Interval 0.44 to 5.58 | percentage of participants | |
| Achievement of ≥75% Decrease From Baseline at Week 4 in the Eczema Area and Severity Index (EASI-75) | Roflumilast Cream 0.15% | 42.0 | 95% Confidence Interval 37.45 to 46.72 | percentage of participants | |
| Achievement of ≥75% Decrease From Baseline at Week 4 in the Eczema Area and Severity Index (EASI-75) | Vehicle Cream | 19.7 | 95% Confidence Interval 15.04 to 25.44 | percentage of participants | |
| Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4 | Roflumilast Cream 0.15% | 39.0 | percentage of participants | ||
| Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4 | Vehicle Cream | 16.9 | percentage of participants | ||
| Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2 | Roflumilast Cream 0.15% | 27.6 | percentage of participants | ||
| Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2 | Vehicle Cream | 10.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04773600/results